Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $14.67

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target [...]

featured-image

BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX – Get Free Report ) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports.

One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $14.67.



Several analysts have recently commented on BCRX shares. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th.

Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities raised their price objective on shares of BioCryst Pharmaceuticals from $15.

00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. StockNews.

com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, Barclays raised their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.

00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Get Our Latest Analysis on BioCryst Pharmaceuticals Hedge Funds Weigh In On BioCryst Pharmaceuticals BioCryst Pharmaceuticals Stock Up 5.3 % NASDAQ:BCRX opened at $8.

19 on Friday. The firm has a market cap of $1.70 billion, a PE ratio of -13.

43 and a beta of 1.89. BioCryst Pharmaceuticals has a 12 month low of $4.

03 and a 12 month high of $8.88. The company’s 50-day moving average price is $7.

75 and its two-hundred day moving average price is $7.07. BioCryst Pharmaceuticals ( NASDAQ:BCRX – Get Free Report ) last announced its earnings results on Monday, November 4th.

The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07).

The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million.

During the same period in the previous year, the firm earned ($0.19) earnings per share. The firm’s revenue was up 35.

1% compared to the same quarter last year. On average, research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile ( Get Free Report BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. See Also Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.

com's FREE daily email newsletter ..